SFN analogs have been found to alter HAT/HDAC activities, histone acetylation status, and associated DNA damage/repair signaling pathways, leading to a reduction in the expression of HDAC3, PCAF, and KAT2A in CRC cells. This evidence concerns the gene KAT2A and colorectal carcinoma.